259 related articles for article (PubMed ID: 31899608)
1. MicroRNA-221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling.
Yin Y; Wang X; Li T; Ren Q; Li L; Sun X; Zhang B; Wang X; Han H; He Y; Cao Z; Sun X; Zhou Z
Cancer Med; 2020 Feb; 9(4):1544-1552. PubMed ID: 31899608
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
[TBL] [Abstract][Full Text] [Related]
3. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract][Full Text] [Related]
4. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway.
Miao Y; Zheng W; Li N; Su Z; Zhao L; Zhou H; Jia L
Sci Rep; 2017 Feb; 7():41942. PubMed ID: 28165066
[TBL] [Abstract][Full Text] [Related]
6. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.
Chen Y; Sun Y; Chen L; Xu X; Zhang X; Wang B; Min L; Liu W
Mol Med Rep; 2013 May; 7(5):1579-84. PubMed ID: 23546450
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
8. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
Zhong S; Li W; Chen Z; Xu J; Zhao J
Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
[TBL] [Abstract][Full Text] [Related]
9. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
10. Effect of miR-7 on resistance of breast cancer cells to adriamycin via regulating EGFR/PI3K signaling pathway.
Huang Q; Wu YY; Xing SJ; Yu ZW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5285-5292. PubMed ID: 31298380
[TBL] [Abstract][Full Text] [Related]
11. USP37 downregulation elevates the Chemical Sensitivity of Human Breast Cancer Cells to Adriamycin.
Qin T; Cui XY; Xiu H; Huang C; Sun ZN; Xu XM; Li LH; Yue L
Int J Med Sci; 2021; 18(2):325-334. PubMed ID: 33390801
[No Abstract] [Full Text] [Related]
12. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
Steelman LS; Navolanic PM; Sokolosky ML; Taylor JR; Lehmann BD; Chappell WH; Abrams SL; Wong EW; Stadelman KM; Terrian DM; Leslie NR; Martelli AM; Stivala F; Libra M; Franklin RA; McCubrey JA
Oncogene; 2008 Jul; 27(29):4086-95. PubMed ID: 18332865
[TBL] [Abstract][Full Text] [Related]
13. Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.
Zhao L; Shan Y; Liu B; Li Y; Jia L
Cell Death Dis; 2017 May; 8(5):e2830. PubMed ID: 28542127
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.
Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM
Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606
[TBL] [Abstract][Full Text] [Related]
15. MiR-202-5p/
Liu T; Guo J; Zhang X
Cancer Biol Ther; 2019; 20(7):989-998. PubMed ID: 30983514
[TBL] [Abstract][Full Text] [Related]
16. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.
Steelman LS; Navolanic P; Chappell WH; Abrams SL; Wong EW; Martelli AM; Cocco L; Stivala F; Libra M; Nicoletti F; Drobot LB; Franklin RA; McCubrey JA
Cell Cycle; 2011 Sep; 10(17):3003-15. PubMed ID: 21869603
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway.
Wang F; Li L; Chen Z; Zhu M; Gu Y
Int J Mol Med; 2016 May; 37(5):1421-8. PubMed ID: 26951965
[TBL] [Abstract][Full Text] [Related]
18. STX3 represses the stability of the tumor suppressor PTEN to activate the PI3K-Akt-mTOR signaling and promotes the growth of breast cancer cells.
Nan H; Han L; Ma J; Yang C; Su R; He J
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1684-1692. PubMed ID: 29408595
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.
Feng R; Dong L
Int J Clin Exp Pathol; 2015; 8(6):6107-16. PubMed ID: 26261488
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]